Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1976 4
1977 1
1978 2
1980 2
1981 3
1982 5
1983 2
1984 3
1985 4
1986 2
1987 2
1988 11
1989 7
1990 10
1991 12
1992 15
1993 8
1994 15
1995 12
1996 13
1997 19
1998 22
1999 26
2000 16
2001 22
2002 21
2003 34
2004 43
2005 40
2006 43
2007 58
2008 64
2009 87
2010 90
2011 80
2012 104
2013 95
2014 122
2015 104
2016 123
2017 99
2018 120
2019 127
2020 135
2021 120
2022 92
2023 95
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

1,905 results

Results by year

Filters applied: . Clear all
Page 1
Malignant pleural mesothelioma.
Chen SE, Pace MB. Chen SE, et al. Am J Health Syst Pharm. 2012 Mar 1;69(5):377-85. doi: 10.2146/ajhp110281. Am J Health Syst Pharm. 2012. PMID: 22345416 Review.
CONCLUSION: Treatment approaches for MPM include surgery, radiation, and systemic chemotherapy. MPM carries a poor prognosis, but recent studies of pemetrexed and platinum analogue combination therapies have demonstrated improved response rates over other treatments....
CONCLUSION: Treatment approaches for MPM include surgery, radiation, and systemic chemotherapy. MPM carries a poor prognosis, but rec …
Pericardial mesothelioma.
Vigneswaran WT, Stefanacci PR. Vigneswaran WT, et al. Curr Treat Options Oncol. 2000 Oct;1(4):299-302. doi: 10.1007/s11864-000-0045-6. Curr Treat Options Oncol. 2000. PMID: 12057155 Review.
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli GL, Soto Parra HJ, Auriati L, Simonassi C. Mencoboni M, et al. Oncol Res Treat. 2017;40(6):364-369. doi: 10.1159/000464410. Epub 2017 May 9. Oncol Res Treat. 2017. PMID: 28472807 Review.
BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evaluated the treatment and outcome of 378 mesothelioma patients referred to 6 Italian Oncology Departments. ...Median survival time was 11.6 mont …
BACKGROUND: Malignant pleural mesothelioma is a problematic condition due to poor prognosis and difficulties in management. We evalua …
Pleural mesothelioma.
Astoul P. Astoul P. Curr Opin Pulm Med. 1999 Jul;5(4):259-68. doi: 10.1097/00063198-199907000-00015. Curr Opin Pulm Med. 1999. PMID: 10407698 Review.
Malignant pleural mesothelioma.
Boutin C, Schlesser M, Frenay C, Astoul P. Boutin C, et al. Eur Respir J. 1998 Oct;12(4):972-81. doi: 10.1183/09031936.98.12040972. Eur Respir J. 1998. PMID: 9817178 Free article. Review.
Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. Perhaps because of this poor prognosis, early screening has incited little interest. However, certain forms may have a better prognosis …
Up to now, no single treatment has been proven to be effective and death usually occurs within about 12-17 months after diagnosis. Perhaps b …
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health.
Neumann V, Löseke S, Nowak D, Herth FJ, Tannapfel A. Neumann V, et al. Dtsch Arztebl Int. 2013 May;110(18):319-26. doi: 10.3238/arztebl.2013.0319. Epub 2013 May 3. Dtsch Arztebl Int. 2013. PMID: 23720698 Free PMC article. Review.
RESULTS: 1397 people died of mesothelioma in Germany in 2010. A plateau in the incidence of the disease is predicted between 2015 and 2030. Most mesotheliomas arise from the pleura. ...The prognosis is still poor, with a median survival time of only 12 months. ...
RESULTS: 1397 people died of mesothelioma in Germany in 2010. A plateau in the incidence of the disease is predicted between 2015 and …
Rate advancement measurement for lung cancer and pleural mesothelioma in asbestos-exposed workers.
Azzolina D, Consonni D, Ferrante D, Mirabelli D, Silvestri S, Luberto F, Angelini A, Cuccaro F, Nannavecchia AM, Oddone E, Vicentini M, Barone-Adesi F, Cena T, Mangone L, Roncaglia F, Sala O, Menegozzo S, Pirastu R, Tunesi S, Chellini E, Miligi L, Perticaroli P, Pettinari A, Bressan V, Merler E, Girardi P, Bisceglia L, Marinaccio A, Massari S, Magnani C; working group. Azzolina D, et al. Thorax. 2023 Aug;78(8):808-815. doi: 10.1136/thorax-2021-217862. Epub 2022 Nov 10. Thorax. 2023. PMID: 36357176
What can independent research for mesothelioma achieve to treat this orphan disease?
Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, Mutti L. Guazzelli A, et al. Expert Opin Investig Drugs. 2019 Aug;28(8):719-732. doi: 10.1080/13543784.2019.1638363. Epub 2019 Jul 1. Expert Opin Investig Drugs. 2019. PMID: 31262194 Review.
Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor prognosis, as current therapies are ineffective. Despite the increased understanding of the molecular biology of mesothelioma, there is still a lack of drugs that dramatically enhance patient …
Introduction: Malignant pleural mesothelioma (MPM) is a rare neoplasm with a poor prognosis, as current therapies are ineffective. De …
Malignant pleural mesothelioma in Finland: regional and gender variation.
Laaksonen S, Ilonen I, Kuosma E, Sutinen E, Wolff H, Vehmas T, Husgafvel-Pursiainen K, Salo JA, Koli K, Räsänen J, Myllärniemi M. Laaksonen S, et al. Acta Oncol. 2019 Jan;58(1):38-44. doi: 10.1080/0284186X.2018.1532599. Epub 2018 Oct 30. Acta Oncol. 2019. PMID: 30375909
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare occupational cancer with a poor prognosis. Even with a multimodality treatment approach, the treatment outcomes remain unsatisfactory. ...The initial survival benefit gained with pemetrexed was diluted at 51 months …
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare occupational cancer with a poor prognosis. Even with a multimodality treat …
1,905 results